Shopping Cart 0
Cart Subtotal
USD 0

Narcolepsy - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Narcolepsy-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy-Pipeline Review, H2 2018, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.

Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Narcolepsy-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 4, 4, 5, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Narcolepsy-Overview

Narcolepsy-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Narcolepsy-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Narcolepsy-Companies Involved in Therapeutics Development

Avadel Pharmaceuticals Plc

Bioprojet SCR

Evotec AG

F. Hoffmann-La Roche Ltd

H.A.C. Pharma

Heptares Therapeutics Ltd

Jazz Pharmaceuticals Plc

Ono Pharmaceutical Co Ltd

OptiNose US Inc

SK Biopharmaceuticals Co Ltd

Taisho Pharmaceutical Holdings Co Ltd

Takeda Pharmaceutical Co Ltd

Theranexus SAS

Narcolepsy-Drug Profiles

(flecainide acetate + modafinil)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arbaclofen-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JZP-258-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JZP-386-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JZP-507-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mazindol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mazindol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-4127-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPN-021-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentylenetetrazol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pitolisant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-5256390-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLS-010-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Orexin Receptor 2 for Narcolepsy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium oxybate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium oxybate ER-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solriamfetol hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVNG-3031-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-925-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TS-091-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XW-10172-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XW-10282-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YNT-185-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Narcolepsy-Dormant Projects

Narcolepsy-Discontinued Products

Narcolepsy-Product Development Milestones

Featured News & Press Releases

Sep 10, 2018: XW Labs appoints clinical development veteran Dr. Daniel Canafax as Chief Medical Officer

Sep 05, 2018: Harmony Biosciences to present data on its investigational product, Pitolisant, at upcoming International Narcolepsy Symposium

Jun 27, 2018: Jazz Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Xyrem (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

Jun 03, 2018: Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy

Jun 03, 2018: Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea

Jun 01, 2018: Suven Life Sciences participating at Sleep 2018 at Baltimore, MD. USA

May 31, 2018: Harmony Biosciences to Present Data On Its Investigational Product, Pitolisant, At Upcoming SLEEP Annual Meeting

May 22, 2018: Bioprojet: Pitolisant Progresses Towards the U.S. Market

May 21, 2018: Harmony Biosciences Receives Breakthrough Therapy And Fast Track Designations For Pitolisant

May 10, 2018: Jazz Pharmaceuticals to Present Data on Sodium Oxybate at SLEEP 2018 Annual Meeting

May 10, 2018: Jazz Pharmaceuticals to Present Data on Solriamfetol at SLEEP 2018 Annual Meeting

May 01, 2018: Jazz Pharmaceuticals Submits Supplemental New Drug Application for Xyrem (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

Mar 22, 2018: AOP Orphan will distribute Wakix (pitolisant) from Bioprojet Pharma in Austria, Nordic countries and Central Eastern Europe

Mar 12, 2018: XW Labs Initiates First-in-Human Phase I Study for Novel Narcolepsy Treatment

Mar 02, 2018: Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Narcolepsy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Narcolepsy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Narcolepsy-Pipeline by Avadel Pharmaceuticals Plc, H2 2018

Narcolepsy-Pipeline by Bioprojet SCR, H2 2018

Narcolepsy-Pipeline by Evotec AG, H2 2018

Narcolepsy-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Narcolepsy-Pipeline by H.A.C. Pharma, H2 2018

Narcolepsy-Pipeline by Heptares Therapeutics Ltd, H2 2018

Narcolepsy-Pipeline by Jazz Pharmaceuticals Plc, H2 2018

Narcolepsy-Pipeline by Ono Pharmaceutical Co Ltd, H2 2018

Narcolepsy-Pipeline by OptiNose US Inc, H2 2018

Narcolepsy-Pipeline by SK Biopharmaceuticals Co Ltd, H2 2018

Narcolepsy-Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2018

Narcolepsy-Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Narcolepsy-Pipeline by Theranexus SAS, H2 2018

Narcolepsy-Dormant Projects, H2 2018

Narcolepsy-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Narcolepsy Therapeutic Products under Development, Key Players in Narcolepsy Therapeutics, Narcolepsy Pipeline Overview, Narcolepsy Pipeline, Narcolepsy Pipeline Assessment


Companies

Avadel Pharmaceuticals Plc

Bioprojet SCR

Evotec AG

F. Hoffmann-La Roche Ltd

H.A.C. Pharma

Heptares Therapeutics Ltd

Jazz Pharmaceuticals Plc

Ono Pharmaceutical Co Ltd

OptiNose US Inc

SK Biopharmaceuticals Co Ltd

Taisho Pharmaceutical Holdings Co Ltd

Takeda Pharmaceutical Co Ltd

Theranexus SAS

Narcolepsy-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy-Pipeline Review, H2 2018, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.

Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Narcolepsy-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 4, 4, 5, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Narcolepsy-Overview

Narcolepsy-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Narcolepsy-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Narcolepsy-Companies Involved in Therapeutics Development

Avadel Pharmaceuticals Plc

Bioprojet SCR

Evotec AG

F. Hoffmann-La Roche Ltd

H.A.C. Pharma

Heptares Therapeutics Ltd

Jazz Pharmaceuticals Plc

Ono Pharmaceutical Co Ltd

OptiNose US Inc

SK Biopharmaceuticals Co Ltd

Taisho Pharmaceutical Holdings Co Ltd

Takeda Pharmaceutical Co Ltd

Theranexus SAS

Narcolepsy-Drug Profiles

(flecainide acetate + modafinil)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arbaclofen-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JZP-258-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JZP-386-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JZP-507-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mazindol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mazindol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-4127-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPN-021-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentylenetetrazol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pitolisant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-5256390-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLS-010-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Orexin Receptor 2 for Narcolepsy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium oxybate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium oxybate ER-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solriamfetol hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVNG-3031-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-925-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TS-091-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XW-10172-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XW-10282-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YNT-185-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Narcolepsy-Dormant Projects

Narcolepsy-Discontinued Products

Narcolepsy-Product Development Milestones

Featured News & Press Releases

Sep 10, 2018: XW Labs appoints clinical development veteran Dr. Daniel Canafax as Chief Medical Officer

Sep 05, 2018: Harmony Biosciences to present data on its investigational product, Pitolisant, at upcoming International Narcolepsy Symposium

Jun 27, 2018: Jazz Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Xyrem (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

Jun 03, 2018: Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy

Jun 03, 2018: Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea

Jun 01, 2018: Suven Life Sciences participating at Sleep 2018 at Baltimore, MD. USA

May 31, 2018: Harmony Biosciences to Present Data On Its Investigational Product, Pitolisant, At Upcoming SLEEP Annual Meeting

May 22, 2018: Bioprojet: Pitolisant Progresses Towards the U.S. Market

May 21, 2018: Harmony Biosciences Receives Breakthrough Therapy And Fast Track Designations For Pitolisant

May 10, 2018: Jazz Pharmaceuticals to Present Data on Sodium Oxybate at SLEEP 2018 Annual Meeting

May 10, 2018: Jazz Pharmaceuticals to Present Data on Solriamfetol at SLEEP 2018 Annual Meeting

May 01, 2018: Jazz Pharmaceuticals Submits Supplemental New Drug Application for Xyrem (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

Mar 22, 2018: AOP Orphan will distribute Wakix (pitolisant) from Bioprojet Pharma in Austria, Nordic countries and Central Eastern Europe

Mar 12, 2018: XW Labs Initiates First-in-Human Phase I Study for Novel Narcolepsy Treatment

Mar 02, 2018: Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Narcolepsy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Narcolepsy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Narcolepsy-Pipeline by Avadel Pharmaceuticals Plc, H2 2018

Narcolepsy-Pipeline by Bioprojet SCR, H2 2018

Narcolepsy-Pipeline by Evotec AG, H2 2018

Narcolepsy-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Narcolepsy-Pipeline by H.A.C. Pharma, H2 2018

Narcolepsy-Pipeline by Heptares Therapeutics Ltd, H2 2018

Narcolepsy-Pipeline by Jazz Pharmaceuticals Plc, H2 2018

Narcolepsy-Pipeline by Ono Pharmaceutical Co Ltd, H2 2018

Narcolepsy-Pipeline by OptiNose US Inc, H2 2018

Narcolepsy-Pipeline by SK Biopharmaceuticals Co Ltd, H2 2018

Narcolepsy-Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2018

Narcolepsy-Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Narcolepsy-Pipeline by Theranexus SAS, H2 2018

Narcolepsy-Dormant Projects, H2 2018

Narcolepsy-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Narcolepsy Therapeutic Products under Development, Key Players in Narcolepsy Therapeutics, Narcolepsy Pipeline Overview, Narcolepsy Pipeline, Narcolepsy Pipeline Assessment


Companies

Avadel Pharmaceuticals Plc

Bioprojet SCR

Evotec AG

F. Hoffmann-La Roche Ltd

H.A.C. Pharma

Heptares Therapeutics Ltd

Jazz Pharmaceuticals Plc

Ono Pharmaceutical Co Ltd

OptiNose US Inc

SK Biopharmaceuticals Co Ltd

Taisho Pharmaceutical Holdings Co Ltd

Takeda Pharmaceutical Co Ltd

Theranexus SAS